TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03890458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEVIT-3
Description: The physicians gave the women in the experimental group vitamin D oral drops in an ampoule of 300,000 IU and a vial of 50,000 IU to take during the IVF treatment. Written and verbal information about how to take vitamin D was provided to the participants by the nurses. The women took 300,000 IU vitamin D orally for the first week. In the second week of the treatment, 50,000 IU vitamin D (15 drops/day) was used as maintenance dose until the pregnancy test day.
Study: NCT02526485

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: A one time blood draw of 150 milliliters will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture.
Study: NCT01733745

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SYSTANE® Lid Wipes
Description: Pre-moistened eyelid cleansing wipes for topical ocular external scrubbing of eyelids and eyelashes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SYSTANE® BALANCE
Description: Lubricant Eye Drops

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SYSTANE® Vitamins

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microfiber towels (as warm compresses, with or without saline eye drops)
Study: NCT05056961

Intervention type: OTHER
Group type: OTHER
Intervention: Multiparametric mesurements
Description: Multiparametric assessments will necessitate the use of a plastic belt to record electro-impedancemetry tomography data; and a nano-gatsric tube fitted with esophageal and gastric low pressure balloons
Study: NCT03300505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given by mouth (PO)
Study: NCT03415373

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle Adapter (Model UAR-2S)
Description: Investigational device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypodermic needle + syringe
Description: Control device
Study: NCT03301441

Intervention type: OTHER
Intervention: questionnaire ef-ID Migraine
Description: All consecutive patients eligible to the study will be included within 7 days of their initial admission, and evaluated with a short questionnaire classifying them as migrainers whose status will undergo a detailed validation at 3 months by a migraine expert, and non-migrainers whose status will be validated by repeating the short questionnaire at the follow-up visit at 3 months.~Initial multimodal imaging, done routinely in any stroke patient, will acquire the raw data necessary to calculate the mismatch ratio (MRI DWI/PWI or CT rCBF/CTP). All radiological data will be analyzed centrally after the end of the recruitment, by investigators blinded to the migraine status.

Intervention type: OTHER
Intervention: questionnaire ef-ID Migraine
Description: All consecutive patients eligible to the study will be included within 7 days of their initial admission, and evaluated with a short questionnaire classifying them as migrainers whose status will undergo a detailed validation at 3 months by a migraine expert, and non-migrainers whose status will be validated by repeating the short questionnaire at the follow-up visit at 3 months.~Initial multimodal imaging, done routinely in any stroke patient, will acquire the raw data necessary to calculate the mismatch ratio (MRI DWI/PWI or CT rCBF/CTP). All radiological data will be analyzed centrally after the end of the recruitment, by investigators blinded to the migraine status.
Study: NCT01254552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iobitridol
Description: Xenetix 350 was administered at a dose up to 180 ml, according to the patient's body weight measured on the day of administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gadoterate meglumine
Description: Dotarem was administered at a dose of 0.1 mmol/kg body weight (0.2 ml/kg body weight)
Study: NCT04651790

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SARS-CoV-2 inactivated vaccine
Description: The vaccine contains inactivated SARS-CoV-2 virus, aluminum hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate and sodium chloride.The final product will be supplied in a pre-filled syringe containing 0.5 ml of solution for injection that corresponds to a dose of the vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 inactivated vaccine
Description: The vaccine contains inactivated SARS-CoV-2 virus, aluminum hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate and sodium chloride.The final product will be supplied in a pre-filled syringe containing 0.5 ml of solution for injection that corresponds to a dose of the vaccine.
Study: NCT00683683

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Knowledge Translation
Description: The multifaceted KT strategy will include 1) local multidisciplinary champions in ED, ICU, and Cardiology 2) A simple protocol for application of hypothermia, tailored to local needs and policy; 3) Identification of perceived and actual barriers to knowledge use; 4) Development of an implementation tool kit and 5) Providing timely feedback on benchmarks for hypothermia and outcomes.
Study: NCT03228628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed 50:50 mixture of nitrous oxide and oxygen
Description: Gaz inhalation will start 5 minutes before the puncture and will be continued until the end of the procedure.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inhale medical air (22% O2 - 78% N2)
Study: NCT04704583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPACE parental-guidance
Description: The treatment will be delivered to the parents in ten 50-minute sessions. The sessions are planned to be weekly and will be completed within 13 weeks of the first session. The sessions include instruction and education, acquiring skills, role-play, and simulations. Parents will be given exercises and goals in reducing accommodation to achieve at home (in cognitive behavioral therapy this is sometimes called 'homework') in some of the sessions. For example, parents to write down one or two things that they would most like to see their child handling better.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SPACE parental-guidance
Description: The treatment will be delivered to the parents in ten 50-minute sessions. The sessions are planned to be weekly and will be completed within 13 weeks of the first session. The sessions include instruction and education, acquiring skills, role-play, and simulations. Parents will be given exercises and goals in reducing accommodation to achieve at home (in cognitive behavioral therapy this is sometimes called 'homework') in some of the sessions. For example, parents to write down one or two things that they would most like to see their child handling better.
Study: NCT02103517

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega -3 fatty acids
Description: Each subject assigned to active treatment group will receive 4 g/day capsule of omega-3 fatty acids.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Corn oil
Description: Each subject assigned to the control group will receive 4 g/day capsule of corn oil.
Study: NCT01310608

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A-View
Description: Pre-operative imaging of the thoracic aorta with A-View technique
Study: NCT03333213

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gua Sha
Study: NCT00845962

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chloroprocaine
Description: spinal administration of chloroprocaine 2%, 40 mg (2 mL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: spinal administration of bupivacaine 0,75% 7,5 mg (1 mL)
Study: NCT02374723

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NuCornea
Description: Deep anterior lamellar corneal transplantation where the NuCornea is substituting a donor cornea

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: donated human corneas
Description: Deep anterior lamellar corneal transplantation with a donated cornea as graft material.
Study: NCT01956604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01312259

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Changing the Interstim parameter of '' Frequency in patients with Interstitial Cystitis
Description: Subjects will be randomized into one of two groups. Group One will be programmed to receive 14 Hz as their frequency, while the other group (Group 2) will receive 40 Hz as their frequency for the first ninety days after surgical implantation. After three months each patient will come in to the office to have their InterStim frequency changed to the opposite frequency. After each patient has had three months to evaluate each of the two frequencies, the next step is to allow the patient to decide which setting they thought best controlled their respective symptoms. The InterStim was then programed to whichever frequency the patient chose, and this would remain for three to six months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Changing the Interstim parameter of '' Frequency in patients with Interstitial Cystitis
Description: Subjects will be randomized into one of two groups. Group One will be programmed to receive 14 Hz as their frequency, while the other group (Group 2) will receive 40 Hz as their frequency for the first ninety days after surgical implantation. After three months each patient will come in to the office to have their InterStim frequency changed to the opposite frequency. After each patient has had three months to evaluate each of the two frequencies, the next step is to allow the patient to decide which setting they thought best controlled their respective symptoms. The InterStim was then programed to whichever frequency the patient chose, and this would remain for three to six months.
Study: NCT00477503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gallium-67 Citrate (Ga-67)
Description: Group A: Ga-67 citrate injection alone, in the baseline study.~Group B: Ga-67 and In 111 DTPA injection in the baseline study.~Group C: Standard of care with Ga-67 and In 111 DTPA injection in baseline study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gallium-67 Citrate (Ga-67)
Description: Group A: Ga-67 citrate injection alone, in the baseline study.~Group B: Ga-67 and In 111 DTPA injection in the baseline study.~Group C: Standard of care with Ga-67 and In 111 DTPA injection in baseline study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gallium-67 Citrate (Ga-67)
Description: Group A: Ga-67 citrate injection alone, in the baseline study.~Group B: Ga-67 and In 111 DTPA injection in the baseline study.~Group C: Standard of care with Ga-67 and In 111 DTPA injection in baseline study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: In-111 DTPA (In-111 pentetate)
Description: Group B: Ga-67 and In 111 DTPA injection in the baseline study.~Group C: Standard of care with Ga-67 and In 111 DTPA injection in baseline study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: In-111 DTPA (In-111 pentetate)
Description: Group B: Ga-67 and In 111 DTPA injection in the baseline study.~Group C: Standard of care with Ga-67 and In 111 DTPA injection in baseline study.
Study: NCT01093677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIM-0705
Description: Oral solution 750 mg LIM 0705 BID for 14 days.
Study: NCT02764437

Intervention type: BIOLOGICAL
Intervention: Whole lung antigen challenge, segmental allergen challenge
Description: Whole lung antigen challenge with housedust mite, short ragweed or cat hair allergen extracts. Segmental allergen challenge with housedust mite, short ragweed or cat hair allergen extracts.
Study: NCT01699724

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JZoloft
Description: 50 mg tablet on Day 1 of each period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline ODT
Description: 50 mg tablet on Day 1 of each period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline ODT
Description: 50 mg tablet on Day 1 of each period
Study: NCT01316718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine
Description: 2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
Study: NCT03993483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unilateral resistance exercise
Description: The participants performed three sets of their unilateral resistance exercise (biceps curls and knee extensions) three times per week for 10 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unilateral resistance exercise
Description: The participants performed three sets of their unilateral resistance exercise (biceps curls and knee extensions) three times per week for 10 weeks.
Study: NCT02582333

Intervention type: OTHER
Intervention: Observation for clinical and virological changes
Description: Only observation after stopping nucleos(t)ide analogue

Intervention type: OTHER
Intervention: Observation for clinical and virological changes
Description: Only observation after stopping nucleos(t)ide analogue
Study: NCT00528307

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HIS buldle ablation
Description: HIS bundle ablation, followed by implant of a biventricular pacemaker

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HIS buldle ablation
Description: HIS bundle ablation, followed by implant of a biventricular pacemaker
Study: NCT03204643

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BH-VPN
Description: A bundle of usual care components, applied consistently and completely, along with access to behavioral health specific patient navigators and navigation services.
Study: NCT00780975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aplidin (plitidepsin)
Description: Aplidin® administered at a starting dose of 5 mg/m2, as a 3-hours intravenous infusion, every 2 weeks.
Study: NCT04525430

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: childbirth education
Description: The 1st Session: General information about labor: Factors affecting labor, early signs of labor, signs of the start of labor, steps of labor, and procedures applied during labor.~The 2nd Session: Methods of coping with birth contractions: Breathing exercises, relaxation exercises, massage, changing position, music, cold/warm application, focus, and walking.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: childbirth education and was subjected to a birth plan
Description: In the birth plan created by the researchers, the pregnant women considered the process from the start of labor to the end of labor and marked the expectation from and preferences about this process on the birth plan.
Study: NCT00012025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Study: NCT02700048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intra-nasal naloxone
Description: 3 doses of intra-nasal naloxone (4 mg each) will be given during controlled hypoglycemic insulin clamps

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intra-nasal saline
Description: 3 doses of intra-nasal saline will be given during controlled hypoglycemic insulin clamps
Study: NCT03247777

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional strengthening
Description: dead lifts, bench press, wrist curls, and lat pulldowns as examples

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional Strengthening
Description: diagonal chops, one leg deadlifts, lateral plyometrics as examples
Study: NCT02946359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib, bevacizumab
Description: Eligible patients with ALK translocation or ROS1 translocation or MET amplification will be treated with Crizotinib at the standard dose of 250 mg BID and bevacizumab at the dose of 7.5mg/kg every three weeks. The dose of crizotinib and bevacizumab may be adjusted depending on the type and severity of toxicity encountered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib, bevacizumab
Description: Eligible patients with ALK translocation or ROS1 translocation or MET amplification will be treated with Crizotinib at the standard dose of 250 mg BID and bevacizumab at the dose of 7.5mg/kg every three weeks. The dose of crizotinib and bevacizumab may be adjusted depending on the type and severity of toxicity encountered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib, bevacizumab
Description: Eligible patients with ALK translocation or ROS1 translocation or MET amplification will be treated with Crizotinib at the standard dose of 250 mg BID and bevacizumab at the dose of 7.5mg/kg every three weeks. The dose of crizotinib and bevacizumab may be adjusted depending on the type and severity of toxicity encountered
Study: NCT02340000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard dose amoxicillin/clavulanate
Description: amoxicillin/clavulanate 875/125 + placebo bid x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose amoxicillin/clavulanate
Description: Time Period I: extended-release amoxicillin/clavulanate 1000/62.5 two tablets bid x 7 days Time Period 2: immediate-release amoxicillin/clavulanate 875/125 plus amoxicllin 875 bid x 7 days
Study: NCT04191889

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hepatic Arterial Infusion combined with Apatinib and Camrelizumab
Description: Drug: FOLFOX Protocol (Oxaliplatin, fluorouracil, and leucovorin); Camrelizumab for injection and Apatinib-Mesylate Tablets~Procedure:~1. On the first day of treatment, HAIC was conducted through a catheter intubated into the tumor feeding artery under DSA guidance with the following chemotherapeutic drugs (mFOLFOX7, oxaliplatin 85 mg/m2 2 hours, folinic acid 400 mg/m2, 5-FU 2500 mg/m2 46 hours) pumped into the tumor artery. The HAIC is repeated every 3 weeks. The cumulative maximum sessions of HAIC is up to 6 times.~2. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally on day 8 in the first HAIC cycle, once a day, for continuous medication.~3. The first dose of Camrelizumab was administered on day 4 of the second HAIC cycle, at a dose of 200 mg intravenously, every three weeks.~4. The cumulative maximum drug use period is up to 2 years. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear.
Study: NCT04549493

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure Therapy
Description: Exposure Therapy is used to reduce the symptoms of PTSD

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure Therapy
Description: Exposure Therapy is used to reduce the symptoms of PTSD

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure Therapy
Description: Exposure Therapy is used to reduce the symptoms of PTSD
Study: NCT02404051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg daily tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg daily tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: 25 mg daily tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: 25 mg daily tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg i.m. on Days 1, 15 and 29 and every 28 days thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg i.m. on Days 1, 15 and 29 and every 28 days thereafter
Study: NCT00492726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (Avelox, BAY12-8039)
Description: Moxifloxacin, 400mg, administered intravenously once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem intravenous
Description: Active treatment: Ertapenem 1.0g, administered intravenously once daily
Study: NCT01604889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ipilimumab
Description: ipilimumab 3 mg/kg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Doses to be determined following the completion of Phase I of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Doses to be determined following the completion of Phase I of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Doses to be determined following the completion of Phase I of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Doses to be determined following the completion of Phase I of the study
Study: NCT00456872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Study: NCT00144599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRA(Tocilizumab)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01039766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: A single intranasal administration of 40 IU of oxytocin will be given to patients up to 6 hours after a traumatic event, with consecutive follow up for 13 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo - saline nasal spray
Description: A single intranasal administration of saline will be given to patients up to 6 hours after a traumatic event, with consecutive follow up for 13 months as the control to the oxytocin arm
Study: NCT02230891

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Carvedilol is a non selective beta blocker

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: Spironolactone is an aldosterone antagonist and can lower blood pressure/ is used in heart failure

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: standard care as per primary care provider